Peer-reviewed veterinary case report
Urinary ACE2 enzyme levels in cats with chronic kidney disease
By Kuo, Tzu-Chien et al.·Published in Frontiers in veterinary science·2024·Institute of Veterinary Clinical Science·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Urinary angiotensin-converting enzyme 2 and its activity in cats with chronic kidney disease.
- Species:
- cat
Plain-English summary
A group of cats with chronic kidney disease (CKD) showed changes in a substance called urinary angiotensin-converting enzyme 2 (uACE2) that could indicate how their kidneys were functioning. In this study, 43 cats with CKD were compared to 24 healthy cats. The CKD cats had higher levels of uACE2 but lower activity compared to the healthy ones, suggesting that as kidney function worsens, uACE2 levels change significantly. However, these changes did not reliably predict how quickly the CKD would progress. Understanding these changes could help veterinarians monitor kidney health in cats.
People also search for: cat chronic kidney disease symptoms · cat kidney disease treatment · what does uACE2 mean in cats
Abstract
INTRODUCTION: Angiotensin-converting enzyme 2 (ACE2) played an important role in the renin-angiotensin-aldosterone system (RAAS) and it was proved to be renoprotective in renal disease. Urinary angiotensin-converting enzyme 2 (uACE2) has been shown to reflect renal injury in human and experimental studies, but its role in feline kidney disease remains unknown. AIMS: Our objectives involve comparing uACE2 concentrations and activities in cats across CKD stages with healthy controls, investigating the relationship between uACE2 concentrations, activities, and clinicopathological data in feline CKD patients, and assessing the predictive abilities of both for CKD progression. METHODS: A retrospective, case-control study. The concentration and activity of uACE2 were measured by commercial ELISA and fluorometric assay kits, respectively. The concentration was adjusted to give uACE2 concentration-to-creatinine ratios (UACCRs). RESULTS: In total, 67 cats consisting of 24 control and 43 chronic kidney disease (CKD), including 24 early-stage CKD and 19 late-stage CKD, were enrolled in this study. UACCR values were significantly higher in both early-stage (2.100 [1.142-4.242] x 10) and late-stage feline CKD (4.343 [2.992-5.0.71] x 10) compared to healthy controls (0.894 [0.610-1.076] x 10; < 0.001), and there was also significant difference between-early stage group and late-stage group (0.026). Urinary ACE2 activity (UAA) was significantly lower in CKD cats (1.338 [0.644-2.755] x pmol/min/ml) compared to the healthy cats (7.989 [3.711-15.903] x pmol/min/ml; < 0.001). UACCR demonstrated an independent, positive correlation with BUN ( < 0.001), and UAA exhibited an independent, negative correlation with plasma creatinine ( < 0.001). Both UACCR and UAA did not yield significant results in predicting CKD progression based on the ROC curve analysis. CONCLUSION AND CLINICAL IMPORTANCE: uACE2 concentration and activity exhibit varying changes as renal function declines, particularly in advanced CKD cats.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38756510/